Actively Recruiting
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma
Led by Ruijin Hospital · Updated on 2025-05-14
30
Participants Needed
1
Research Sites
409 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A\>G polymorphism as predictive biomarker
CONDITIONS
Official Title
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 8 and 65 years
- Confirmed diagnosis of advanced bone and soft tissue sarcoma excluding adipocytic tumor
- Identification of pulmonary lesion is mandatory
- Refractory to prior treatment with standard first-line chemotherapy as per NCCN guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with life expectancy greater than 3 months
- Adequate kidney, liver, and blood function; normal or controlled blood pressure
- Advanced stage where complete surgical removal of all lesions is not possible
- No serious chest-related conditions and adequate lung function for daily activities
- Previously treated with tyrosine kinase inhibitors (TKIs) for less than 8 weeks but stopped due to manageable complications that have resolved
You will not qualify if you...
- Having other types of malignant tumors at the same time
- Cardiac insufficiency or arrhythmia
- Uncontrolled complications such as diabetes mellitus
- Blood clotting disorders or bleeding diseases
- Pleural or peritoneal fluid needing surgical treatment
- Other infections or wound complications
- Poor wound healing or soft tissue problems around implant areas at baseline
- Previously treated with VEGFR TKIs for more than 8 weeks
- Previously treated with VEGFR TKIs but stopped due to cancer assessment or dose-limiting complications despite adequate interventions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
W
Weibin Zhang, PhD, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here